Zeto, Inc., an EEG technology leader, has assembled a jury of top neurology experts to select groundbreaking clinical trials it will sponsor, aiming to enhance EEG applications in healthcare.
Zeto, Inc., a pioneering EEG brain monitoring company based in Santa Clara, California, has recently unveiled a prominent jury consisting of renowned experts in neurology and neuroscience for its first-ever clinical trial sponsorship program. This initiative aims to foster advancements in EEG technology applications in clinical research, particularly focusing on improving patient care and biomedical research.
The jury panel includes distinguished figures such as Dr. Robert Fisher, Director of the Stanford Epilepsy Center and Zeto’s Chief Medical Advisor. Dr. Fisher’s accolades include recognition by the ‘Best Doctors in America’ since 1996 and several prestigious awards from international neurological societies.
Joining him on this esteemed panel is Dr. Michael Weisend, celebrated for his innovative contributions to cognitive neuroscience and brain stimulation technologies. Dr. Weisend’s varied experiences across academia, government, and industry offer a broad perspective crucial for evaluating the innovative applications of EEG research in clinical settings.
The third member of the panel, Dr. Pradeep Modur, brings his expertise as a board-certified epileptologist and the director of Ascension Seton’s Comprehensive Epilepsy Program. Dr. Modur’s academic role and his involvement in neurological research add another layer of depth to the panel’s collective expertise.
This illustrious panel has been entrusted with the task of evaluating the submissions received by Zeto, following a call for proposals announced at the 2023 Society for Neuroscience Convention in Washington D.C. The criteria for selection include alignment with Zeto’s vision, potential impact on patient care, and the innovative use of EEG in the proposed research. The process has been highly competitive, attracting a plethora of high-quality proposals reflecting the excitement within the scientific community about Zeto’s state-of-the-art EEG technology.
Zeto’s EEG platform, particularly notable for its FDA-approved WR19 wireless headset with active, dry electrodes, has revolutionized how EEGs are performed. It allows for quicker setup and enhanced patient comfort, factors that are crucial in both clinical and research settings. The technology’s potential to improve access to and the quality of EEG testing is significant, especially in the context of expanding the scopes of adjacent biomedical research and clinical trials.
The selected projects will be announced by June 10th, 2024, with Zeto ready to sponsor up to three clinical trials. These trials are anticipated to play a pivotal role in further demonstrating the efficacy and broadening the applications of Zeto’s innovative EEG solutions.
Considering the caliber of the jury and the innovative nature of the trials, the outcomes will be keenly awaited by both the medical community and the wider public interested in advancements in neurology and patient care technologies. The findings could herald a new era of EEG research, potentially setting new benchmarks in diagnostics and patient-centric care.
